Abstract:BACKGROUND: Sufficient dose of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid regimen may be an ideal treatment option for renal transplant recipients, and the regimen has been widely used in clinic due to its low nephrotoxicity, few adverse reactions and strong immunosuppressive effects. OBJECTIVE: To investigate the efficacy and safety of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid regimen in renal transplantation patients with the control of mycophenolate mofetil combined with standard-dose tacrolimus and corticosteroid. METHODS: A total of 210 patients receiving a single-organ renal al ograft were randomly divided into standard-dose tacrolimus group (n=104) and low-dose tacrolimus group (n=106). Individual patients were treated for 12 months. The primary efficacy endpoints were the chronic al ograft damage index and glomerular filtration rate at 12 months after transplantation. The secondary efficacy end points mainly included the acute rejection rate, treatment failure rate, and the survival rate of patient and transplant kidney. The safety parameters such as new onset of post-transplantation diabetes mel itus, hypertension and hyperlipidemia were also evaluated. RESULTS AND CONCLUSION: The vast majorities of patients were administrated with sufficient dose of mycophenolate mofetil (1.5 g/d or above) in two groups. The majority of the patients in standard-dose tacrolimus group had the mean trough level below the protocol-defined, which led to the similar mean trough level between standard-dose and low-dose tacrolimus group. These could also confirm that the regimen of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid had been wildly accepted and used by clinicians. The efficacy and safety of two groups were similar. The mean chronic al ograft damage index of the renal pathological changes at 12 months after transplantation in standard-dose and low-dose tacrolimus group were 1.82 and 2.13 respectively (P=0.081 3), the mean glomerular filtration rates were 77.08 mL/min and 80.12 mL/min (P=0.794 9), acute rejection rates were 2.6% and 5.2% (P=0.681 2), and the survival rates of patients and transplant kidney were 100% and 99.1% (P=1.000 0). The rates of new onset of post-transplantation diabetes mel itus in the standard-dose and low-dose tacrolimus group were 2.9% and 1.9%, and the rates of hyperlipidemia were 2.9% and 3.8%, respectively. For the regimen of mycophenolate mofetil combined with tacrolimus and corticosteroid, the utilization of sufficient dose of mycophenolate mofetil could reduce the dose of tacrolimus, thereby significantly reducing the nephrotoxicity, hyperlipidemia and new onset of post-transplantation diabetes mel itus caused by tacrolimus and achieving a good balance of efficacy and toxicity when maintaining a strong immune inhibition and reducing the acute rejection incidence successful y.

CLINICAL APPLICATION OF DEOXYSCHIZANDRIN IN PATIENTS AFTER LIVER TRANSPLANTATION

The Application of FK506 Based Quadruple Immunosuppression Therapy in Clinical Liver Transplantation

Influential Factors and Regulation of FK506 C/D after Liver Transplantation

The Comparison of Two Immunosuppression Schemes Containing Tacrolimus in Renal Transplant Recipients

Effect of Switch from Cyclosporine to FK506 on Renal Graft Outcome in Patients after Initial Acute Rejection

Clinical Analysis of 2520 Renal Transplantations in One Center

Improved Clinical Outcomes in Chinese Renal Allograft Recipients Receiving Lower Dose Immunosuppressants

Optimal immunosuppressor induces stable gut microbiota after liver transplantation.

Comparison of the efficacy of low-dosage versus standard-dosage tacrolimus after kidney transplantation by programming renal biopsies

A Meta-Analysis of Therapeutic Effect of Cyclosporine Microemulsion and Tacrolimus for Patients Undergoing Liver Transplantation

Immunotherapeutic and monitoring of tacrolimus in recipients of liver transplantation

CLINICAL USE OF FK506 AS PRIMARY ANTI-REJECTION AGENT IN RENAL ALLOGRAFT RECIPEINTS

Immunosuppressive Therapy in Pediatric Cadaveric Renal Transplantation

Treatment of rejection and highly sensitized in kidney transplantation with double filtration plasmapheresis

A Pilot Clinical Study of Tacrolimus(fk506) in Cadavaric Renal Transplant Recipients with Delayed Graft Function and Early Acute Rejection

Double Filtration Plasmapheresis Combined with Daclizumab in the Treatment for Sensitized Recipients of Cadaver Kidney Transplantation

Application of Mycophenolate Mofetil Combined with Low-Dose Tacrolimus and Corticosteroid Regimen after Renal Transplantation

Individualized immunosuppressive regimens for long-term surviving liver transplant recipients with chronic renal dysfunction

The optimal immunosuppressant after liver transplantation according to diagnosis: Cyclosporine A or FK506?

Fk506 Caused 2 Cases Liver Damage after Kidney Transplantation and Review of Literature

FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation